Alzheimer's disease

Seminars in Neurology

Volumn 27, Issue 1, 2007, Pages 32-41

  Yaari, Roy ^a   Corey Bloom, Jody ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Clinical presentation; Dementia; Diagnosis; Pathophysiology; Treatment

Indexed keywords

ALPHA TOCOPHEROL; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; DESIPRAMINE; DONEPEZIL; ESTROGEN; GALANTAMINE; GINKGO BILOBA EXTRACT; HUPERZINE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMANTINE; MOOD STABILIZER; NEUROLEPTIC AGENT; NORTRIPTYLINE; PREDNISONE; RIVASTIGMINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

AGITATION; ALZHEIMER DISEASE; ANOREXIA; ANTICHOLINERGIC EFFECT; ARTICLE; BEHAVIOR DISORDER; BRAIN FUNCTION; CAREGIVER; COGNITIVE DEFECT; CONFUSION; DEPRESSION; DEPTH PERCEPTION; DIARRHEA; DISABILITY; DISEASE COURSE; DIZZINESS; DRUG MEGADOSE; EXTRAPYRAMIDAL SYMPTOM; FALLING; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEALTH CARE COST; HOME CARE; HUMAN; HYPOTENSION; INSOMNIA; LEG CRAMP; NAUSEA; NEUROFIBRILLARY TANGLE; NEUROPSYCHOLOGICAL TEST; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPITE CARE; SEDATION; SIDE EFFECT; SOCIAL SUPPORT; TARDIVE DYSKINESIA; UNITED STATES; VIVID DREAM; VOMITING; WEIGHT REDUCTION;

ALZHEIMER DISEASE; APOLIPOPROTEINS E; BRAIN; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEUROFIBRILLARY TANGLES; NOOTROPIC AGENTS; SENILE PLAQUES;

EID: 33846939769     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-956753     Document Type: Article

References (37)

1. Alzheimer A. Uber eine eigenartige Erkangkung der Hirnrinde. Allgemaine Zeitschrift fur Psychiatrie und Psychisch-Gerichtliche Medizin 1907;64:146-148
2. (English translation in: Arch Neurol 1967;21:109-110)
3. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60: 1119-1122
4. Ernst RL, Hay JW. Economic research on Alzheimer disease: a review of the literature. Alzheimer Dis Assoc Disord 1997;11(suppl 6):135-145
5. Bayer TA, Wirths O, Majtenyi K, et al. Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol 2001;11:1-11
6. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356
7. Carter J, Lippa CF. Beta-amyloid, neuronal death and Alzheimer's disease. Curr Mol Med 2001;1:733-737
8. Cummings JL, Vinters HV, Cole GM, Khachaturian ZS. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998;51(suppl 1):S2-S17
9. Mirra SS, Hart MN, Terry RD. Making the diagnosis of Alzheimer's disease: a primer for practicing pathologists. Arch Pathol Lab Med 1993;117:132-144
10. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486
11. Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 1997;56:1095-1097
12. Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A. Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 2000;54:2072-2077
13. Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry 1998;55:809-815
14. van Duijn CM, Clayton D, Chandra V, et al. Familial aggregation of Alzheimer's disease and related disorders: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 1991;20(suppl 2):S13-S20
15. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA 1997;278:1349-1356
16. Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 1994;271:1004-1010
17. Schmand B, Smit JH, Geerlings MI, Lindeboom J. The effects of intelligence and education on the development of dementia: a test of the brain reserve hypothesis. Psychol Med 1997;27:1337-1344
18. Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life: findings from the Nun Study. JAMA 1996;275:528-532
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944
20. Galasko D, Hansen LA, Katzman R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994;51:888-895
21. Salmon DP, Thomas RG, Pay MM, et al. Alzheimer's disease can be accurately diagnosed in very mildly impaired individuals. Neurology 2002;59:1022-1028
22. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-1153
23. Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001;58:373-379
24. DeCarli C. The role of neuroimaging in dementia. Clin Geriatr Med 2001;17:255-279
25. Hoffman JM, Welsh-Bohmer KA, Hanson M, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000;41:1920-1928
26. Bergman H, Chertkow H, Wolfson C, et al. HM-PAO (CERETEC) SPECT brain scanning in the diagnosis of Alzheimer's disease. J Am Geriatr Soc 1997;45:15-20
27. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740-2754
28. Thai LJ, Kantarci K, Reiman EM, et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20:6-15
29. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-147
30. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-1166
31. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev 2003;9:275-308
32. Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev 2005;(3):CD003154
33. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-324
34. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-1222
35. Tabet N, Birks J, Grimley Evans J. Vitamin E for Alzheimer's disease. Cochrane Database Syst Rev 2000; (4):CD002854
36. Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46
37. Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2002;(4):CD003120